CN109432504B — 一种成骨基因干预功能材料及其制备方法
Assigned to Fourth Medical Center General Hospital of Chinese PLA · Expires 2021-11-16 · 5y expired
What this patent protects
本发明公开了一种成骨基因干预功能材料,由靶向分子‑脂质体‑siRNA与煅烧骨复合而成,靶向分子‑脂质体‑siRNA由耦合有靶向分子的脂质体包裹siRNA而成;并且公开了成骨基因干预功能材料的制备方法。靶向分子‑脂质体‑siRNA与煅烧骨复合而成的成骨基因干预功能材料与成骨界面亲和,在减少siRNA扩散降解的同时使siRNA定向作用于临近成骨界面的成骨细胞和骨母细胞,进而调节成骨细胞和骨母细胞的功能,提高局部成骨活性,获得优越的骨修复质量。
USPTO Abstract
本发明公开了一种成骨基因干预功能材料,由靶向分子‑脂质体‑siRNA与煅烧骨复合而成,靶向分子‑脂质体‑siRNA由耦合有靶向分子的脂质体包裹siRNA而成;并且公开了成骨基因干预功能材料的制备方法。靶向分子‑脂质体‑siRNA与煅烧骨复合而成的成骨基因干预功能材料与成骨界面亲和,在减少siRNA扩散降解的同时使siRNA定向作用于临近成骨界面的成骨细胞和骨母细胞,进而调节成骨细胞和骨母细胞的功能,提高局部成骨活性,获得优越的骨修复质量。
Drugs covered by this patent
- Onpattro (PATISIRAN SODIUM) · Alnylam Pharmaceuticals
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.